Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept
| Status: | Completed |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 3/1/2014 |
| Start Date: | December 2010 |
| End Date: | December 2013 |
| Contact: | Andrew M Naidech, MD MSPH |
| Email: | a-naidech@northwestern.edu |
| Phone: | 312-503-3593 |
The investigators intend to show that DDAVP improves platelet activity from baseline to 60
minutes after treatment start.
minutes after treatment start.
Inclusion Criteria:
- Spontaneous intracerebral hemorrhage as documented by head CT scan
- Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction
units (ARU), indicating anti-platelet medication
Exclusion Criteria:
- International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use
- History of von Willebrand disease
- Pregnancy
- Known hypersensitivity to DDAVP or desmopressin
- Active cardiovascular disease or unstable angina
- Hyponatremia or history of hyponatremia
- Current or historical deep venous thrombosis or pulmonary embolism
We found this trial at
1
site
Northwestern Memorial Hospital Northwestern Memorial is an academic medical center hospital where the patient comes...
Click here to add this to my saved trials
